Korean Red Ginseng extract ameliorates demyelination by inhibiting infiltration and activation of immune cells in cuprizone-administrated mice

[1]  T. Möllenkamp,et al.  Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination , 2022, Histochemistry and Cell Biology.

[2]  D. Mahns,et al.  The roles of microglia and astrocytes in phagocytosis and myelination: Insights from the cuprizone model of multiple sclerosis , 2022, Glia.

[3]  S. Nah,et al.  Gintonin mitigates experimental autoimmune encephalomyelitis by stabilization of Nrf2 signaling via stimulation of lysophosphatidic acid receptors , 2020, Brain, Behavior, and Immunity.

[4]  Sung Won Kim,et al.  Immuno-enhancement effects of Korean Red Ginseng in healthy adults: a randomized, double-blind, placebo-controlled trial , 2020, Journal of ginseng research.

[5]  Zubair Ahmed Ratan,et al.  Pharmacological potential of ginseng and its major component ginsenosides , 2020, Journal of ginseng research.

[6]  Sung Won Kim,et al.  Physiological and pharmacological features of the non-saponin components in Korean Red Ginseng , 2020, Journal of ginseng research.

[7]  Li Yang,et al.  Phytochemical analysis of Panax species: a review , 2020, Journal of ginseng research.

[8]  M. Hemmatzadeh,et al.  The role of immune regulatory molecules in multiple sclerosis , 2019, Journal of Neuroimmunology.

[9]  F. Shi,et al.  Temporal and Spatial Dynamics of Astroglial Reaction and Immune Response in Cuprizone-Induced Demyelination , 2019, Neurotoxicity Research.

[10]  S. Nah,et al.  Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington’s disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors , 2019, Brain, Behavior, and Immunity.

[11]  O. Akinola,et al.  Cuprizone toxicity and Garcinia kola biflavonoid complex activity on hippocampal morphology and neurobehaviour , 2019, Heliyon.

[12]  B. Xiao,et al.  Effect of Fasudil on remyelination following cuprizone‐induced demyelination , 2019, CNS neuroscience & therapeutics.

[13]  Qiaojun He,et al.  Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis , 2019, Front. Pharmacol..

[14]  R. Brambilla.  The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis , 2019, Acta Neuropathologica.

[15]  M. Ghasemi-Kasman,et al.  A Review of Herbal Therapy in Multiple Sclerosis , 2018, Advanced pharmaceutical bulletin.

[16]  B. Sharrack,et al.  Animal models of multiple sclerosis: From rodents to zebrafish , 2018, Multiple sclerosis.

[17]  B. Yoo,et al.  Ginsenosides: the need to move forward from bench to clinical trials , 2018, Journal of ginseng research.

[18]  Hyun Il Kim,et al.  Non-clinical pharmacokinetic behavior of ginsenosides , 2018, Journal of ginseng research.

[19]  S. Nah,et al.  Multi-Target Protective Effects of Gintonin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Mediated Model of Parkinson’s Disease via Lysophosphatidic Acid Receptors , 2018, Front. Pharmacol..

[20]  S. Nah,et al.  Multitarget effects of Korean Red Ginseng in animal model of Parkinson's disease: antiapoptosis, antioxidant, antiinflammation, and maintenance of blood–brain barrier integrity , 2018, Journal of ginseng research.

[21]  P. De Sarno,et al.  Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes , 2017, Front. Immunol..

[22]  S. Nah,et al.  Korean Red Ginseng mitigates spinal demyelination in a model of acute multiple sclerosis by downregulating p38 mitogen-activated protein kinase and nuclear factor-κB signaling pathways , 2017, Journal of ginseng research.

[23]  Xia Zhang,et al.  Multiple sclerosis: Pathology, diagnosis and treatments , 2017, Experimental and therapeutic medicine.

[24]  Hyunkyoung Lee,et al.  IKKβ-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1/Th17 cell activation and compromising blood brain barrier , 2016, Molecular Neurodegeneration.

[25]  D. Hafler,et al.  Multiple sclerosis: genetics, biomarkers, treatments. , 2016, Current opinion in neurology.

[26]  S. Nah,et al.  Korean Red Ginseng and Ginsenoside-Rb1/-Rg1 Alleviate Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells and Upregulating Regulatory T Cells , 2016, Molecular Neurobiology.

[27]  Sung-Hoon Kim,et al.  Bee Venom Acupuncture Alleviates Experimental Autoimmune Encephalomyelitis by Upregulating Regulatory T Cells and Suppressing Th1 and Th17 Responses , 2016, Molecular Neurobiology.

[28]  Rongshi Li,et al.  Natural Product‐Based Drug Discovery , 2016, Medicinal research reviews.

[29]  Min Jung Lee,et al.  An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response , 2015, PloS one.

[30]  Manuel A. Friese,et al.  Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.

[31]  P. Calabresi,et al.  Transfer of Myelin-Reactive Th17 Cells Impairs Endogenous Remyelination in the Central Nervous System of Cuprizone-Fed Mice , 2015, The Journal of Neuroscience.

[32]  Young-Sook Kim,et al.  Safety Analysis of Panax Ginseng in Randomized Clinical Trials: A Systematic Review , 2015, Medicines.

[33]  Sang Myung Lee,et al.  Characterization of Korean Red Ginseng (Panax ginseng Meyer): History, preparation method, and chemical composition , 2015, Journal of ginseng research.

[34]  Annemie Van der Linden,et al.  Neuroscience and Biobehavioral Reviews Cellular and Molecular Neuropathology of the Cuprizone Mouse Model: Clinical Relevance for Multiple Sclerosis , 2022 .

[35]  A. Maghazachi,et al.  Multiple sclerosis and the role of immune cells. , 2014, World journal of experimental medicine.

[36]  M. Stangel,et al.  Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned , 2014, Front. Cell. Neurosci..

[37]  V. Yong,et al.  The Benefits and Detriments of Macrophages/Microglia in Models of Multiple Sclerosis , 2013, Clinical & developmental immunology.

[38]  S. Miller,et al.  Cytokine Control of Inflammation and Repair in the Pathology of Multiple Sclerosis , 2012, The Yale journal of biology and medicine.

[39]  L. Steinman.  The discovery of natalizumab, a potent therapeutic for multiple sclerosis , 2012, The Journal of cell biology.

[40]  S. Lazic,et al.  A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.

[41]  I. Cho.  Effects of Panax ginseng in Neurodegenerative Diseases , 2012, Journal of ginseng research.

[42]  D. Hafler,et al.  Fingolimod for multiple sclerosis. , 2012, The New England journal of medicine.

[43]  H. Lassmann,et al.  The molecular basis of neurodegeneration in multiple sclerosis , 2011, FEBS letters.

[44]  N. Tubridy,et al.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis , 2010, Clinical and experimental immunology.

[45]  Soheyla Mahdavian,et al.  Multiple Sclerosis , 2010, Journal of pharmacy practice.

[46]  Sjef Copray,et al.  The cuprizone animal model: new insights into an old story , 2009, Acta Neuropathologica.

[47]  J. Crabbe,et al.  Calibration of rotational acceleration for the rotarod test of rodent motor coordination , 2009, Journal of Neuroscience Methods.

[48]  K. Myhr,et al.  The cuprizone model for demyelination , 2008, Acta neurologica Scandinavica. Supplementum.

[49]  E. Vilella,et al.  Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. , 2007, Toxicology letters.

[50]  Y. Imai,et al.  Microglia/macrophage‐specific protein Iba1 binds to fimbrin and enhances its actin‐bundling activity , 2004, Journal of neurochemistry.

[51]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[52]  R. Milne,et al.  Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? , 2001, Journal of neurology, neurosurgery, and psychiatry.

[53]  S. Kulkarni,et al.  Elevated plus-maze: a novel psychobehavioral tool to measure anxiety in rodents. , 1991, Methods and findings in experimental and clinical pharmacology.

[54]  V. ter meulen,et al.  Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Hyoung-Chun Kim,et al.  Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing. , 2012, Journal of Alzheimer's disease : JAD.